HRP20140688T1 - Inhibitori piroltriazin kinaze - Google Patents

Inhibitori piroltriazin kinaze Download PDF

Info

Publication number: HRP20140688T1
Authority: HR; Croatia
Prior art keywords: substituted; alkyl; cycloalkyl; ylamino; pyrrolo
Prior art date: 2006-07-07

Application number

HRP20140688TT

Other languages

English (en)

Croatian (hr)

Inventor

Harold Mastalerz

Mark D. Wittman

Kurt Zimmermann

Mark G. Saulnier

Upender Velaparthi

Dolatrai M. Vyas

Guifen Zhang

Walter Lewis Johnson

David B. Frennesson

Xiaopeng Sang

Peiying Liu

David R. Langley

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-07

Filing date

2014-07-17

Publication date

2014-10-24

2014-07-17 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2014-10-24 Publication of HRP20140688T1 publication Critical patent/HRP20140688T1/hr

Links

SUPXSFXAMJPEPH-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]triazine Chemical compound N1=NC=C2NC=CC2=N1 SUPXSFXAMJPEPH-UHFFFAOYSA-N 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 claims 57
125000000623 heterocyclic group Chemical group 0.000 claims 43
-1 ureido, cyano, sulfonamido, substituted sulfonamido Chemical class 0.000 claims 35
150000001408 amides Chemical class 0.000 claims 31
229910052739 hydrogen Inorganic materials 0.000 claims 31
239000001257 hydrogen Substances 0.000 claims 31
150000002431 hydrogen Chemical class 0.000 claims 27
125000000547 substituted alkyl group Chemical group 0.000 claims 27
125000001424 substituent group Chemical group 0.000 claims 26
125000002837 carbocyclic group Chemical group 0.000 claims 25
125000000753 cycloalkyl group Chemical group 0.000 claims 25
229910052736 halogen Inorganic materials 0.000 claims 23
150000002367 halogens Chemical class 0.000 claims 23
125000003118 aryl group Chemical group 0.000 claims 20
239000000126 substance Substances 0.000 claims 20
125000003545 alkoxy group Chemical group 0.000 claims 19
125000005346 substituted cycloalkyl group Chemical group 0.000 claims 19
125000003282 alkyl amino group Chemical group 0.000 claims 16
125000004356 hydroxy functional group Chemical group O* 0.000 claims 16
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical class NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 15
125000003342 alkenyl group Chemical group 0.000 claims 15
125000004390 alkyl sulfonyl group Chemical group 0.000 claims 15
125000000392 cycloalkenyl group Chemical group 0.000 claims 15
125000001072 heteroaryl group Chemical group 0.000 claims 15
229920006395 saturated elastomer Polymers 0.000 claims 15
125000004414 alkyl thio group Chemical group 0.000 claims 14
125000001118 alkylidene group Chemical group 0.000 claims 14
125000000304 alkynyl group Chemical group 0.000 claims 14
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 14
125000001589 carboacyl group Chemical group 0.000 claims 13
125000003107 substituted aryl group Chemical group 0.000 claims 13
125000004448 alkyl carbonyl group Chemical group 0.000 claims 12
125000001188 haloalkyl group Chemical group 0.000 claims 11
125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
125000004103 aminoalkyl group Chemical group 0.000 claims 10
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 10
125000004438 haloalkoxy group Chemical group 0.000 claims 10
125000005017 substituted alkenyl group Chemical group 0.000 claims 10
229940124530 sulfonamide Drugs 0.000 claims 10
150000003456 sulfonamides Chemical class 0.000 claims 10
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 10
125000004423 acyloxy group Chemical group 0.000 claims 9
125000005236 alkanoylamino group Chemical group 0.000 claims 9
229910052799 carbon Inorganic materials 0.000 claims 9
125000004426 substituted alkynyl group Chemical group 0.000 claims 9
125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 8
125000004644 alkyl sulfinyl group Chemical group 0.000 claims 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
125000004043 oxo group Chemical group O=* 0.000 claims 8
125000004001 thioalkyl group Chemical group 0.000 claims 8
125000001691 aryl alkyl amino group Chemical group 0.000 claims 7
125000003710 aryl alkyl group Chemical group 0.000 claims 7
125000004659 aryl alkyl thio group Chemical group 0.000 claims 7
125000001769 aryl amino group Chemical group 0.000 claims 7
125000005110 aryl thio group Chemical group 0.000 claims 7
125000004104 aryloxy group Chemical group 0.000 claims 7
125000004093 cyano group Chemical group *C#N 0.000 claims 7
125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
125000005140 aralkylsulfonyl group Chemical group 0.000 claims 6
125000005239 aroylamino group Chemical group 0.000 claims 6
125000002102 aryl alkyloxo group Chemical group 0.000 claims 6
125000004391 aryl sulfonyl group Chemical group 0.000 claims 6
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 claims 6
150000003839 salts Chemical class 0.000 claims 6
XIKRJRRZTIMYRY-UHFFFAOYSA-N (cyanosulfonylamino)urea Chemical class NC(=O)NNS(=O)(=O)C#N XIKRJRRZTIMYRY-UHFFFAOYSA-N 0.000 claims 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
102000001253 Protein Kinase Human genes 0.000 claims 5
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 5
125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims 5
125000004658 aryl carbonyl amino group Chemical group 0.000 claims 5
125000005160 aryl oxy alkyl group Chemical group 0.000 claims 5
125000005325 aryloxy aryl group Chemical group 0.000 claims 5
125000002619 bicyclic group Chemical group 0.000 claims 5
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 5
125000001475 halogen functional group Chemical group 0.000 claims 5
125000004404 heteroalkyl group Chemical group 0.000 claims 5
125000005114 heteroarylalkoxy group Chemical group 0.000 claims 5
125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
125000005553 heteroaryloxy group Chemical group 0.000 claims 5
125000002768 hydroxyalkyl group Chemical group 0.000 claims 5
125000002950 monocyclic group Chemical group 0.000 claims 5
108060006633 protein kinase Proteins 0.000 claims 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
206010028980 Neoplasm Diseases 0.000 claims 4
201000011510 cancer Diseases 0.000 claims 4
125000004432 carbon atom Chemical group C* 0.000 claims 4
125000004663 dialkyl amino group Chemical group 0.000 claims 4
208000035475 disorder Diseases 0.000 claims 4
125000003396 thiol group Chemical class [H]S* 0.000 claims 4
101100439665 Arabidopsis thaliana SWI2 gene Proteins 0.000 claims 3
108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 3
102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 3
150000004657 carbamic acid derivatives Chemical class 0.000 claims 3
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
210000000496 pancreas Anatomy 0.000 claims 3
POARIJJCCJDSKV-HNNXBMFYSA-N (2s)-1-[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-n-(1,3-thiazol-2-yl)pyrrolidine-2-carboxamide Chemical compound O=C([C@H]1N(CCC1)C1=NN2C=CC=C2C(NC2=NNC(=C2)C2CC2)=N1)NC1=NC=CS1 POARIJJCCJDSKV-HNNXBMFYSA-N 0.000 claims 2
FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims 2
208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
241000124008 Mammalia Species 0.000 claims 2
208000000172 Medulloblastoma Diseases 0.000 claims 2
208000034578 Multiple myelomas Diseases 0.000 claims 2
206010029260 Neuroblastoma Diseases 0.000 claims 2
206010035226 Plasma cell myeloma Diseases 0.000 claims 2
206010060862 Prostate cancer Diseases 0.000 claims 2
208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
210000000481 breast Anatomy 0.000 claims 2
210000001072 colon Anatomy 0.000 claims 2
201000010099 disease Diseases 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 2
208000005017 glioblastoma Diseases 0.000 claims 2
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 2
210000004072 lung Anatomy 0.000 claims 2
201000001441 melanoma Diseases 0.000 claims 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
210000001672 ovary Anatomy 0.000 claims 2
229910052760 oxygen Inorganic materials 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
230000002062 proliferating effect Effects 0.000 claims 2
229910052717 sulfur Inorganic materials 0.000 claims 2
210000001685 thyroid gland Anatomy 0.000 claims 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
QDVKRHSEGADNGG-SFHVURJKSA-N (2s)-1-[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-n-pyridin-3-ylpyrrolidine-2-carboxamide Chemical compound O=C([C@H]1N(CCC1)C1=NN2C=CC=C2C(NC2=NNC(=C2)C2CC2)=N1)NC1=CC=CN=C1 QDVKRHSEGADNGG-SFHVURJKSA-N 0.000 claims 1
BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 1
206010000599 Acromegaly Diseases 0.000 claims 1
208000023275 Autoimmune disease Diseases 0.000 claims 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
208000011231 Crohn disease Diseases 0.000 claims 1
102000003909 Cyclin E Human genes 0.000 claims 1
108090000257 Cyclin E Proteins 0.000 claims 1
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 1
102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 1
108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 1
101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 claims 1
101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 1
101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
101150111783 NTRK1 gene Proteins 0.000 claims 1
101150056950 Ntrk2 gene Proteins 0.000 claims 1
102100024924 Protein kinase C alpha type Human genes 0.000 claims 1
101150001535 SRC gene Proteins 0.000 claims 1
102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 1
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 1
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 1
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 1
230000032683 aging Effects 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
239000002246 antineoplastic agent Substances 0.000 claims 1
125000004181 carboxyalkyl group Chemical group 0.000 claims 1
239000002254 cytotoxic agent Substances 0.000 claims 1
229940127089 cytotoxic agent Drugs 0.000 claims 1
231100000599 cytotoxic agent Toxicity 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
230000000694 effects Effects 0.000 claims 1
125000002541 furyl group Chemical group 0.000 claims 1
230000003463 hyperproliferative effect Effects 0.000 claims 1
125000002883 imidazolyl group Chemical group 0.000 claims 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
125000003226 pyrazolyl group Chemical group 0.000 claims 1
125000004076 pyridyl group Chemical group 0.000 claims 1
125000000714 pyrimidinyl group Chemical group 0.000 claims 1
125000000335 thiazolyl group Chemical group 0.000 claims 1
125000001544 thienyl group Chemical group 0.000 claims 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HRP20140688TT 2006-07-07 2014-07-17 Inhibitori piroltriazin kinaze HRP20140688T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US81917106P	2006-07-07	2006-07-07
PCT/US2007/072697 WO2008005956A2 (en)	2006-07-07	2007-07-03	Pyrrolotriazine kinase inhibitors

Publications (1)

Publication Number	Publication Date
HRP20140688T1 true HRP20140688T1 (hr)	2014-10-24

Family

ID=38671050

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20140688TT HRP20140688T1 (hr)	2006-07-07	2014-07-17	Inhibitori piroltriazin kinaze

Country Status (26)

Country	Link
US (4)	US7534792B2 (pl)
EP (1)	EP2041138B1 (pl)
JP (1)	JP5185930B2 (pl)
KR (1)	KR101443400B1 (pl)
CN (1)	CN101511835B (pl)
AR (1)	AR061873A1 (pl)
AU (1)	AU2007269163B2 (pl)
BR (1)	BRPI0714359A2 (pl)
CA (1)	CA2657594C (pl)
CL (1)	CL2007001995A1 (pl)
CO (1)	CO6220940A2 (pl)
DK (1)	DK2041138T3 (pl)
EA (1)	EA018322B1 (pl)
ES (1)	ES2493566T3 (pl)
HR (1)	HRP20140688T1 (pl)
IL (1)	IL196033A0 (pl)
MX (1)	MX2008016517A (pl)
NO (1)	NO342385B1 (pl)
NZ (1)	NZ574189A (pl)
PE (1)	PE20080677A1 (pl)
PL (1)	PL2041138T3 (pl)
PT (1)	PT2041138E (pl)
SI (1)	SI2041138T1 (pl)
TW (1)	TWI393722B (pl)
WO (1)	WO2008005956A2 (pl)
ZA (1)	ZA200900109B (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101501023A (zh) *	2006-07-07	2009-08-05	贝林格尔.英格海姆国际有限公司	苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途
EP2041138B1 (en) *	2006-07-07	2014-06-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
JP5319659B2 (ja) *	2007-04-18	2013-10-16	ブリストル−マイヤーズスクイブカンパニー	ピロロトリアジンキナーゼ阻害剤
WO2008144345A2 (en) *	2007-05-17	2008-11-27	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
PE20090837A1 (es) *	2007-07-02	2009-07-24	Boehringer Ingelheim Int	Nuevos compuestos quimicos
WO2009003998A2 (en) *	2007-07-02	2009-01-08	Boehringer Ingelheim International Gmbh	Antiproliferative compounds based on 5-membered heterocycles
US8212031B2 (en)	2008-03-06	2012-07-03	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
UY32146A (es)	2008-09-29	2010-04-30	Boehringer Ingelheim Int	Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos
CN102245610B (zh) *	2008-10-08	2014-04-30	百时美施贵宝公司	吡咯并三嗪激酶抑制剂
EP2376491B1 (en)	2008-12-19	2015-03-04	Cephalon, Inc.	Pyrrolotriazines as alk and jak2 inhibitors
US20120220594A1 (en)	2009-10-30	2012-08-30	Bristol-Meyers Squibb Company	Methods for treating cancer in patients having igf-1r inhibitor resistance
WO2011083391A2 (en)	2010-01-05	2011-07-14	Pfizer Inc.	Biomarkers for anti-igf-ir cancer therapy
CN102725294B (zh) *	2010-02-03	2015-09-02	百时美施贵宝公司	(s)-1-(4-(5-环丙基-1h-吡唑-3-基氨基)吡咯并[1,2-f][1,2,4]三嗪-2-基)-n-(6-氟吡啶-3-基)-2-甲基吡咯烷-2-甲酰胺的晶型
JP5093527B2 (ja) *	2010-02-10	2012-12-12	日本電気株式会社	複合光導波路、波長可変フィルタ、波長可変レーザ、および光集積回路
JP5871897B2 (ja)	2010-03-26	2016-03-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピリジルトリアゾール
US9290507B2 (en)	2010-03-26	2016-03-22	Boehringer Ingelheim International Gmbh	B-RAF kinase inhibitors
WO2011123493A1 (en)	2010-03-31	2011-10-06	Bristol-Myers Squibb Company	Substituted pyrrolotriazines as protein kinase inhibitors
US8710055B2 (en)	2010-12-21	2014-04-29	Boehringer Ingelheim International Gmbh	Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN102584828B (zh) *	2011-01-14	2016-01-27	上海艾力斯医药科技有限公司	吡咯烷[3，4-d]嘧啶衍生物、制备方法及其应用
US20140309229A1 (en)	2011-10-13	2014-10-16	Bristol-Myers Squibb Company	Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
JP6099051B2 (ja)	2011-10-25	2017-03-22	塩野義製薬株式会社	Ｐｇｄ２受容体アンタゴニスト活性を有するへテロ環誘導体
CN103450204B (zh)	2012-05-31	2016-08-17	中国科学院上海药物研究所	吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9724352B2 (en)	2012-05-31	2017-08-08	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
US9499519B2 (en)	2012-12-26	2016-11-22	Medivation Technologies, Inc.	Fused pyrimidine compounds and use thereof
US9050345B2 (en)	2013-03-11	2015-06-09	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
EP2970231A1 (en)	2013-03-15	2016-01-20	Blueprint Medicines Corporation	Piperazine derivatives and their use as kit modulators
WO2015058129A1 (en)	2013-10-17	2015-04-23	Blueprint Medicines Corporation	Compositions useful for treating disorders related to kit
DK3057969T3 (en) *	2013-10-17	2018-09-24	Blueprint Medicines Corp	COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT
WO2015081783A1 (zh) *	2013-12-06	2015-06-11	江苏奥赛康药业股份有限公司	吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
WO2015126808A2 (en) *	2014-02-18	2015-08-27	Baldwin John J	Hbv assay
US10231965B2 (en)	2014-02-20	2019-03-19	Ignyta, Inc.	Molecules for administration to ROS1 mutant cancer cells
CN104974163B (zh) *	2014-04-14	2017-11-07	广东东阳光药业有限公司	取代的杂芳基化合物及其组合物和用途
US9688680B2 (en)	2014-08-04	2017-06-27	Blueprint Medicines Corporation	Compositions useful for treating disorders related to kit
CA2969540C (en)	2014-12-02	2023-03-21	Ignyta, Inc.	Combinations for the treatment of neuroblastoma
EP3325481B1 (en)	2015-07-24	2019-06-12	Blueprint Medicines Corporation	Compounds useful for treating disorders related to kit and pdgfr
CN108697661A (zh)	2015-12-18	2018-10-23	亚尼塔公司	用于治疗癌症的组合
CN109311886B (zh) *	2016-06-23	2021-11-09	豪夫迈·罗氏有限公司	[1,2,3]***并[4,5-d]嘧啶衍生物
MX2019008229A (es)	2017-01-10	2019-10-24	Bayer Ag	Derivados heterociclicos como agentes de control de plagas.
CN110312718B (zh)	2017-01-10	2023-02-28	拜耳公司	作为害虫防治剂的杂环烯衍生物
WO2018183712A1 (en)	2017-03-31	2018-10-04	Blueprint Medicines Corporation	Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
EP3392267A1 (en)	2017-04-18	2018-10-24	Myr GmbH	Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors
AR112027A1 (es)	2017-06-15	2019-09-11	Biocryst Pharm Inc	Inhibidores de alk 2 quinasa que contienen imidazol
JP7203083B2 (ja)	2017-07-19	2023-01-12	イグナイタインコーポレイテッド	エントレクチニブを含む薬学的組成物
CN111225662B (zh)	2017-10-17	2022-11-22	伊尼塔公司	药物组合物和剂型
US20220153748A1 (en)	2019-04-12	2022-05-19	Blueprint Medicines Corporation	Pyrrolotriazine derivatives for treating kit-and pdgfra-mediated diseases
PT3856341T (pt)	2019-04-12	2023-12-12	Blueprint Medicines Corp	Formas cristalinas de (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1- metil-1h-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4- il)piperazinil)pirimidin-5-il)etan-1-amina e métodos de preparação
JP7343622B2 (ja) *	2019-06-14	2023-09-12	シージーンテック（スーチョウ，チャイナ）カンパニーリミテッド	Ｆｇｆｒとｖｅｇｆｒ二重阻害剤としての縮合環系化合物
WO2021257857A1 (en)	2020-06-19	2021-12-23	Incyte Corporation	Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en)	2020-06-19	2023-09-12	Incyte Corporation	Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2022006456A1 (en)	2020-07-02	2022-01-06	Incyte Corporation	Tricyclic pyridone compounds as jak2 v617f inhibitors
AU2021300429A1 (en)	2020-07-02	2023-02-16	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en)	2020-08-27	2023-05-30	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en)	2020-12-21	2024-03-05	Incyte Corporation	Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
KR102612407B1 (ko) *	2021-01-14	2023-12-11	환인제약 주식회사	Ｂｍｓ－７５４８０７ 화합물을 유효성분으로 포함하는 신경염증성 질환의 예방 또는 치료용 약학적 조성물
TW202302589A (zh)	2021-02-25	2023-01-16	美商英塞特公司	作為ｊａｋ２ｖ６１７ｆ抑制劑之螺環內醯胺
CN112679407B (zh) *	2021-03-17	2021-06-04	南京桦冠生物技术有限公司	一种手性5-取代脯氨酸类化合物的制备方法
CA3233636A1 (en) *	2021-09-29	2023-04-06	Repare Therapeutics Inc.	N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta
WO2024069592A1 (en) *	2022-09-29	2024-04-04	Repare Therapeutics Inc.	N-(5-substituted-[(l,3,4-thiadiazolyl) or (l,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use
CN116178358B (zh) *	2022-11-04	2024-04-19	济南大学	一种靶向c-Src激酶SH3结构域的化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6982265B1 (en) *	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
WO2000071129A1 (en)	1999-05-21	2000-11-30	Bristol-Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
EP1543009A4 (en) *	2002-08-02	2007-08-08	Bristol Myers Squibb Co	Pyrrolotriazine KINASE INHIBITORS
DE602005023333D1 (de) *	2004-10-15	2010-10-14	Takeda Pharmaceutical	Kinaseinhibitoren
EP2041138B1 (en) *	2006-07-07	2014-06-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
EP2049542B1 (en) *	2006-08-09	2012-09-19	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7531539B2 (en)	2006-08-09	2009-05-12	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7982033B2 (en) *	2006-11-03	2011-07-19	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors

2007
- 2007-07-03 EP EP07799265.9A patent/EP2041138B1/en active Active
- 2007-07-03 PL PL07799265T patent/PL2041138T3/pl unknown
- 2007-07-03 JP JP2009519588A patent/JP5185930B2/ja not_active Expired - Fee Related
- 2007-07-03 BR BRPI0714359-1A patent/BRPI0714359A2/pt active Search and Examination
- 2007-07-03 MX MX2008016517A patent/MX2008016517A/es active IP Right Grant
- 2007-07-03 CA CA2657594A patent/CA2657594C/en not_active Expired - Fee Related
- 2007-07-03 CN CN2007800327558A patent/CN101511835B/zh not_active Expired - Fee Related
- 2007-07-03 AU AU2007269163A patent/AU2007269163B2/en not_active Ceased
- 2007-07-03 ES ES07799265.9T patent/ES2493566T3/es active Active
- 2007-07-03 KR KR1020097002487A patent/KR101443400B1/ko active IP Right Grant
- 2007-07-03 NZ NZ574189A patent/NZ574189A/en unknown
- 2007-07-03 EA EA200900152A patent/EA018322B1/ru not_active IP Right Cessation
- 2007-07-03 PT PT77992659T patent/PT2041138E/pt unknown
- 2007-07-03 DK DK07799265.9T patent/DK2041138T3/da active
- 2007-07-03 SI SI200731488T patent/SI2041138T1/sl unknown
- 2007-07-03 WO PCT/US2007/072697 patent/WO2008005956A2/en active Application Filing
- 2007-07-05 PE PE2007000874A patent/PE20080677A1/es active IP Right Grant
- 2007-07-05 US US11/773,466 patent/US7534792B2/en active Active
- 2007-07-06 CL CL2007001995A patent/CL2007001995A1/es unknown
- 2007-07-06 TW TW096124588A patent/TWI393722B/zh not_active IP Right Cessation
- 2007-07-10 AR ARP070103070A patent/AR061873A1/es not_active Application Discontinuation
2008
- 2008-12-18 IL IL196033A patent/IL196033A0/en active IP Right Grant
2009
- 2009-01-05 NO NO20090025A patent/NO342385B1/no not_active IP Right Cessation
- 2009-01-06 CO CO09000765A patent/CO6220940A2/es active IP Right Grant
- 2009-01-06 ZA ZA200900109A patent/ZA200900109B/xx unknown
- 2009-03-26 US US12/411,724 patent/US7879855B2/en active Active
2011
- 2011-01-28 US US13/015,687 patent/US8263765B2/en active Active
2012
- 2012-08-07 US US13/568,750 patent/US8592579B2/en active Active
2014
- 2014-07-17 HR HRP20140688TT patent/HRP20140688T1/hr unknown

Also Published As

Publication number	Publication date
JP2009542814A (ja)	2009-12-03
PL2041138T3 (pl)	2014-11-28
DK2041138T3 (da)	2014-08-11
CN101511835A (zh)	2009-08-19
JP5185930B2 (ja)	2013-04-17
CO6220940A2 (es)	2010-11-19
NZ574189A (en)	2011-03-31
CA2657594A1 (en)	2008-01-10
MX2008016517A (es)	2009-01-19
WO2008005956A3 (en)	2008-03-06
CA2657594C (en)	2012-01-17
US20120302747A1 (en)	2012-11-29
EP2041138A2 (en)	2009-04-01
EA200900152A1 (ru)	2009-06-30
SI2041138T1 (sl)	2014-08-29
NO342385B1 (no)	2018-05-14
US8592579B2 (en)	2013-11-26
PT2041138E (pt)	2014-10-07
IL196033A0 (en)	2009-09-01
ZA200900109B (en)	2010-03-31
CN101511835B (zh)	2013-11-27
AU2007269163B2 (en)	2011-07-28
KR101443400B1 (ko)	2014-10-02
ES2493566T3 (es)	2014-09-12
KR20090027764A (ko)	2009-03-17
EA018322B1 (ru)	2013-07-30
US8263765B2 (en)	2012-09-11
US7534792B2 (en)	2009-05-19
US20080009497A1 (en)	2008-01-10
WO2008005956A2 (en)	2008-01-10
US20110124623A1 (en)	2011-05-26
US7879855B2 (en)	2011-02-01
AU2007269163A1 (en)	2008-01-10
US20090239838A1 (en)	2009-09-24
AR061873A1 (es)	2008-09-24
CL2007001995A1 (es)	2008-01-25
TW200813059A (en)	2008-03-16
TWI393722B (zh)	2013-04-21
NO20090025L (no)	2009-02-02
EP2041138B1 (en)	2014-06-25
PE20080677A1 (es)	2008-06-26
BRPI0714359A2 (pt)	2013-02-26

Publication	Publication Date	Title
HRP20140688T1 (hr)	2014-10-24	Inhibitori piroltriazin kinaze
CN109328187B (zh)	2022-04-26	一种具有fgfr抑制活性的新型化合物及其制备和应用
RU2345996C1 (ru)	2009-02-10	Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
RU2401265C2 (ru)	2010-10-10	Соединения и композиции в качестве ингибиторов протеинкиназы
US9422267B2 (en)	2016-08-23	Fused pyrimidine compounds and use thereof
RU2434010C2 (ru)	2011-11-20	Новое амидное производное для ингибирования роста раковых клеток
ES2393410T3 (es)	2012-12-21	Pirrolotriazinas inhibidoras de quinasas
US20070282101A1 (en)	2007-12-06	Indazole compounds
KR20090090383A (ko)	2009-08-25	이미다조티아졸 유도체
US20040019046A1 (en)	2004-01-29	Phenylacetamido-pyrazole derivatives and their use as antitumor agents
RU2012143689A (ru)	2014-04-20	Спироциклические соединения и их применение в качестве терапевтических агентов и диагностических зондов
JP2008501675A5 (pl)	2008-04-10
HRP20100401T1 (hr)	2010-09-30	DERIVATI PIRAZOLO/3,4-d/AZEPINA KAO HISTAMINSKI H3 ANTAGONISTI
RU2010123923A (ru)	2012-01-10	Производные изоксазоло-пиридина
TW200534853A (en)	2005-11-01	Synergistic methods and compositions for treating cancer
JP2009513575A5 (pl)	2010-11-11
RU2013143028A (ru)	2015-04-10	Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
RU2013155456A (ru)	2015-06-20	Соединения пирролидинилмочевины и пирролидинилтиомочевины как ингибиторы киназы trka
IL277579B (en)	2022-09-01	Piperidinone derivatives as mdm2 inhibitors for cancer therapy
RU2012143794A (ru)	2014-05-10	Производные n-(имидазопиримидин-7-ил)-гетероаламидов и их применение в качестве ингибиторов pde10a
CZ20013677A3 (cs)	2002-06-12	Cyklické inhibitory protein tyrosin kinasy
RU2011111592A (ru)	2013-02-10	Замещенные аминоинданы и их аналоги и их применение в фармацевтике
JP2013522286A5 (pl)	2014-04-17
RU2008108939A (ru)	2009-09-20	Замещенные имидазолы, фармацевтическая композиция, способ лечения заболевания, связанного по крайней мере с активностью ksp, способ ингибирования ksp, лекарственное средство для лечения рака
JP2011524363A5 (pl)	2012-07-26